secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001104659-22-105560
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer exercises option on Voyager TRACER capsid for rare CNS disease; $10M fee
-------------------------------------------------------------------------------

- Pfizer exercised License Option for Voyager's novel capsid for an undisclosed rare neurologic CNS disease gene therapy program.
- Voyager receives $10M upfront fee and is eligible for future development, regulatory and sales milestone payments plus royalties.
- Pfizer did not exercise option for cardiovascular target; rights for that target revert to Voyager.
- Option follows prior agreement from Oct 2021 under which Pfizer evaluated Capsids through Sept 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922105560/0001104659-22-105560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922105560/tm2227299d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-105560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer